Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 12070.145 | 0.9024 | 0.8175 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 12070.145 | 0.9009 | 0.8147 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 12070.145 | 0.9013 | 0.8155 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 12070.145 | 0.9125 | 0.8364 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 4 | uM | 12070.145 | 0.7145 | 0.4623 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 20 | uM | 12070.145 | 0.4156 | -0.1171 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 100 | uM | 12070.145 | 0.6179 | 0.2774 | 1.0737 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 12112.145 | 0.9398 | 0.9366 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 12112.145 | 0.8812 | 0.8728 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 12112.145 | 0.9575 | 0.9554 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 12112.145 | 0.9550 | 0.9527 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 12112.145 | 0.9217 | 0.9170 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 12112.145 | 0.7999 | 0.7809 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 4 | uM | 12112.145 | 0.7107 | 0.6748 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 20 | uM | 12112.145 | 0.3339 | 0.1311 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Bosutinib | Src | nRTK | 100 | uM | 12112.145 | 0.2940 | 0.0587 | 1.9247 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 10753.145 | 0.9557 | 0.9411 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 10753.145 | 0.8912 | 0.8538 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 10753.145 | 0.9332 | 0.9110 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 10753.145 | 0.9411 | 0.9216 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 10753.145 | 1.0564 | 1.0736 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 10753.145 | 0.8619 | 0.8134 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 4 | uM | 10753.145 | 0.6074 | 0.4401 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 20 | uM | 10753.145 | 0.2200 | -0.2623 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Bosutinib | Src | nRTK | 100 | uM | 10753.145 | 0.1668 | -0.3854 | 1.5180 |